Q-omics provides the consensus-scored TLR9 profile across patient tissues and cancer cell-line models. TLR9 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TLR9 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TLR9 RNA expression shows 15,916 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, KIRC, and KIRP as cancer lineages where TLR9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLR9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLR9 survival associations across molecular data types. TLR9 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLR9 RNA expression–survival associations across cancer types. High TLR9 expression shows unfavorable associations in UCEC, KIRC, ACC, READ and LIHC, but favorable associations in SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TLR9 RNA expression.
This table summarizes TLR9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TLR9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLR9 shows lower tumor expression in BLCA, BRCA and LUSC and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher TLR9 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p < 0.001).
This table shows molecular features associated with TLR9 in patient tissues and cancer cell lines. In patient samples, TLR9 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TLR9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
